Department of Health Restoration, West Virginia University School of Nursing, Morgantown, USA.
Brain Res Bull. 2012 Jul 1;88(4):313-9. doi: 10.1016/j.brainresbull.2012.02.002. Epub 2012 Feb 21.
The molecular causality and response to stroke is complex. Yet, much of the literature examining the molecular response to stroke has focused on targeted pathways that have been well-characterized. Consequently, our understanding of stroke pathophysiology has made little progress by way of clinical therapeutics since tissue plasminogen activator was approved for treatment nearly a decade ago. The lack of clinical translation is in part due to neuron-focused studies, preclinical models of cerebral ischemia and the paradoxical nature of neuro-inflammation. With the evolution of the Stroke Therapy Academic Industry Roundtable criteria streamlining research efforts and broad availability of genomic technologies, the ability to decipher the molecular fingerprint of ischemic stroke is on the horizon. This review highlights preclinical microarray findings of the ischemic brain, discusses the transcriptome of cerebral preconditioning and emphasizes the importance of further characterizing the role of the neurovascular unit and peripheral white blood cells in mediating stroke damage and repair within the penumbra.
中风的分子因果关系和反应非常复杂。然而,许多研究中风分子反应的文献都集中在已经得到充分描述的靶向途径上。因此,自近十年前组织型纤溶酶原激活物被批准用于治疗以来,我们对中风病理生理学的理解几乎没有通过临床治疗取得任何进展。缺乏临床转化部分归因于以神经元为中心的研究、脑缺血的临床前模型以及神经炎症的矛盾性质。随着中风治疗学术产业圆桌会议标准的发展,简化了研究工作,基因组技术广泛可用,解析缺血性中风分子指纹的能力即将实现。这篇综述强调了缺血性大脑的临床前微阵列研究结果,讨论了脑预处理的转录组,并强调了进一步描述神经血管单元和外周白细胞在介导半影区中风损伤和修复中的作用的重要性。